AR100049A1 - Derivados de dihidrotiazina y dihidrooxazina con actividad inhibidora de bace1 - Google Patents

Derivados de dihidrotiazina y dihidrooxazina con actividad inhibidora de bace1

Info

Publication number
AR100049A1
AR100049A1 ARP150101090A ARP150101090A AR100049A1 AR 100049 A1 AR100049 A1 AR 100049A1 AR P150101090 A ARP150101090 A AR P150101090A AR P150101090 A ARP150101090 A AR P150101090A AR 100049 A1 AR100049 A1 AR 100049A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
alkyl
compound
halogen
Prior art date
Application number
ARP150101090A
Other languages
English (en)
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of AR100049A1 publication Critical patent/AR100049A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto que tiene un efecto inhibidor de la producción de amiloide b, en especial un efecto de inhibición de BACE1 y que es útil como un agente terapéutico o preventivo para enfermedades inducidas por producción, secreción y/o deposición de proteínas amiloide b. Reivindicación 1: Un compuesto de la fórmula (1) caracterizado porque X es -S- u -O-, (i) cuando X es -S-, entonces R³ᵃ es alquilo, haloalquilo, hidroxialquilo o alquiloxialquilo, R²ᵃ es halógeno, alquiloxi o haloalquiloxi y R²ᵃ puede ser alquilo cuando R³ᵃ es haloalquilo, R²ᵇ es H, R²ᵃ y R²ᵇ junto con el átomo de carbono al que se unen pueden formar cicloalcano sustituido, R³ᵃ puede ser H cuando R²ᵃ y R²ᵇ junto con el átomo de carbono al que se unen pueden formar cicloalcano sustituido, (ii) cuando X es -O-, luego R³ᵃ es haloalquilo opcionalmente sustituido con uno o varios seleccionados de alquiloxi y cicloalquilo o cicloalquilo sustituido con uno o varios seleccionados de halógeno, R²ᵃ es H, halógeno, alquilo, alquiloxi o haloalquiloxi, R²ᵇ es H, R²ᵃ y R²ᵇ junto con el átomo de carbono al que se unen pueden formar cicloalcano sustituido, R³ᵃ puede ser H o alquilo cuando R²ᵃ y R²ᵇ junto con el átomo de carbono al que se unen pueden formar cicloalcano sustituido, R³ᵇ es H o alquilo, el resto de fórmula (2) puede ser un compuesto de fórmula (3); el anillo A es un carbociclo aromático sustituido o no sustituido, un carbociclo no aromático sustituido o no sustituido, un heterociclo aromático sustituido o no sustituido o un heterociclo no aromático sustituido o no sustituido; el anillo B es un carbociclo aromático sustituido o no sustituido, un carbociclo no aromático sustituido o no sustituido, un heterociclo aromático sustituido o no sustituido o un heterociclo no aromático sustituido o no sustituido; R¹ es alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido o cicloalquilo sustituido o no sustituido; R⁵ es halógeno o alquilo sustituido o no sustituido; n es un número entero de 0 a 2; siempre que se excluyan los siguientes compuestos: (i) un compuesto, en donde X es -O-, R³ᵃ es CH₂F o CF₃, R³ᵇ es H, R²ᵃ es H o F y R²ᵇ es H, (ii) un compuesto, en donde X es -O-, R³ᵃ es CHF₂, R³ᵇ es H, R²ᵃ es OMe y R²ᵇ es H, (iii) el compuesto representado por las fórmulas (4), (5) y (6); o una de sus sales farmacéuticamente aceptables.
ARP150101090A 2014-04-11 2015-04-10 Derivados de dihidrotiazina y dihidrooxazina con actividad inhibidora de bace1 AR100049A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014081524 2014-04-11

Publications (1)

Publication Number Publication Date
AR100049A1 true AR100049A1 (es) 2016-09-07

Family

ID=53284477

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101090A AR100049A1 (es) 2014-04-11 2015-04-10 Derivados de dihidrotiazina y dihidrooxazina con actividad inhibidora de bace1

Country Status (15)

Country Link
US (1) US20170073337A1 (es)
EP (1) EP3129370A1 (es)
JP (1) JP2017510587A (es)
KR (1) KR20160141849A (es)
CN (1) CN106414431A (es)
AR (1) AR100049A1 (es)
AU (1) AU2015244702A1 (es)
CA (1) CA2945272A1 (es)
EA (1) EA201692048A1 (es)
IL (1) IL248228A0 (es)
MX (1) MX2016013035A (es)
PH (1) PH12016501891A1 (es)
SG (1) SG11201607999VA (es)
TW (1) TW201623295A (es)
WO (1) WO2015156421A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999980B2 (en) † 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
SG11201507196WA (en) 2013-03-08 2015-10-29 Amgen Inc Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
UA117695C2 (uk) 2014-02-19 2018-09-10 Х. Луннбек А/С 2-аміно-3,5,5-трифтор-3,4,5,6-тетрагідропіридини як інгібітори bace1 для лікування хвороби альцгеймера
WO2016022724A1 (en) 2014-08-08 2016-02-11 Amgen Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
WO2016149057A1 (en) * 2015-03-19 2016-09-22 Eli Lilly And Company Selective bace1 inhibitors
TW201717948A (zh) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
KR20180033524A (ko) 2015-08-12 2018-04-03 하. 룬드벡 아크티에셀스카브 Bace1 저해제로서의 2-아미노-3-플루오로-3-(플루오로메틸)-6-메틸-6-페닐-3,4,5,6-테트라하이드로피리딘
WO2017061534A1 (en) 2015-10-08 2017-04-13 Shionogi & Co., Ltd. Dihydrothiazine derivatives
CN108699051B (zh) * 2016-03-01 2021-12-24 豪夫迈·罗氏有限公司 Bace1抑制剂
BR112020021728A2 (pt) * 2018-04-27 2021-01-26 Shionogi & Co., Ltd. derivados de tetra-hidropiranooxazina tendo atividade inibitória de bace1 seletiva
JP7127808B2 (ja) * 2018-05-29 2022-08-30 国立大学法人山口大学 フルオロアルキル基を含有するイミン類の製造方法
EP3875021A4 (en) * 2018-11-01 2021-10-20 FUJIFILM Corporation MEDICAL IMAGE PROCESSING APPARATUS, MEDICAL IMAGE PROCESSING PROCESS AND DIAGNOSIS ASSISTANCE APPARATUS

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2006138217A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
ES2476027T3 (es) * 2005-10-25 2014-07-11 Shionogi & Co., Ltd. Derivados de aminodihidrotriazina
ES2476605T3 (es) 2007-04-24 2014-07-15 Shionogi & Co., Ltd. Derivados de aminohidrotiazina sustituidos con grupos cíclicos
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
AU2009258496B8 (en) 2008-06-13 2014-06-26 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
WO2010113848A1 (ja) 2009-03-31 2010-10-07 塩野義製薬株式会社 Ｂａｃｅ１阻害作用を有するイソチオウレア誘導体またはイソウレア誘導体
CN102686584A (zh) 2009-11-13 2012-09-19 盐野义制药株式会社 具有氨基连接基的氨基噻嗪或氨基噁嗪衍生物
JPWO2011070781A1 (ja) * 2009-12-09 2013-04-22 塩野義製薬株式会社 置換アミノチアジン誘導体
WO2011071057A1 (ja) 2009-12-09 2011-06-16 塩野義製薬株式会社 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物
US7964594B1 (en) 2009-12-10 2011-06-21 Hoffmann-La Roche Inc. Amino oxazine derivatives
EP2511269A4 (en) 2009-12-11 2013-04-24 Shionogi & Co FUSED HETEROCYCLIC COMPOUND HAVING AN AMINO GROUP
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
EP2518059A4 (en) 2009-12-24 2013-05-29 Shionogi & Co 4-AMINO-1,3-THIAZINE OR OXAZINE DERIVATIVE
EP2634186A4 (en) 2010-10-29 2014-03-26 Shionogi & Co naphthyridine
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
US8404680B2 (en) 2011-02-08 2013-03-26 Hoffmann-La Roche Inc. N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
JPWO2012147762A1 (ja) 2011-04-26 2014-07-28 塩野義製薬株式会社 ピリジン誘導体およびそれを含有するｂａｃｅ１阻害剤
TW201247635A (en) 2011-04-26 2012-12-01 Shionogi & Co Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
JP2012250933A (ja) 2011-06-03 2012-12-20 Shionogi & Co Ltd オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物
CA2837252A1 (en) 2011-06-07 2012-12-13 F. Hoffmann-La Roche Ag Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
EP2718287A1 (en) 2011-06-07 2014-04-16 F.Hoffmann-La Roche Ag [1,3]oxazines
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
US20130073953A1 (en) 2011-09-21 2013-03-21 Timothy Onyenobi News headline screenshot viewing system
UA113538C2 (xx) * 2012-01-26 2017-02-10 Фторметил-5,6-дигідро-4h-$1,3]оксазини
KR20150023450A (ko) 2012-06-26 2015-03-05 에프. 호프만-라 로슈 아게 Bace1 억제제로서의 다이플루오로-헥사하이드로-사이클로펜타옥사진일 및 다이플루오로-헥사하이드로-벤조옥사진일
WO2014010748A1 (en) 2012-07-10 2014-01-16 Shionogi & Co., Ltd. Cyclopropane derivative having bace1 inhibiting activity
JP2014101354A (ja) 2012-10-24 2014-06-05 Shionogi & Co Ltd Ｂａｃｅ１阻害作用を有するオキサジン誘導体
WO2014065434A1 (en) * 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
JP2014101353A (ja) 2012-10-26 2014-06-05 Shionogi & Co Ltd オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物
WO2014098831A1 (en) 2012-12-19 2014-06-26 Bristol-Myers Squibb Company 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production
JP2016505055A (ja) 2013-01-22 2016-02-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂａｃｅ１阻害剤としてのフルオロ−［１，３］オキサジン
US9296734B2 (en) 2013-03-01 2016-03-29 Amgen Inc. Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
BR112015019412A8 (pt) 2013-04-11 2019-11-12 Hoffmann La Roche inibidores de bace1, seus usos, e composição farmacêutica

Also Published As

Publication number Publication date
MX2016013035A (es) 2017-01-09
CN106414431A (zh) 2017-02-15
PH12016501891A1 (en) 2016-12-19
EA201692048A1 (ru) 2017-04-28
EP3129370A1 (en) 2017-02-15
KR20160141849A (ko) 2016-12-09
TW201623295A (zh) 2016-07-01
IL248228A0 (en) 2016-11-30
JP2017510587A (ja) 2017-04-13
AU2015244702A1 (en) 2016-10-06
WO2015156421A1 (en) 2015-10-15
US20170073337A1 (en) 2017-03-16
SG11201607999VA (en) 2016-10-28
CA2945272A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
AR100049A1 (es) Derivados de dihidrotiazina y dihidrooxazina con actividad inhibidora de bace1
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
SV2016005328A (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
CO2018004124A2 (es) Compuestos heterocíclicos
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
AR103222A1 (es) Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
AR099376A1 (es) Compuestos de diaminopirimidilo sustituidos, sus composiciones y métodos de tratamiento con aquellos
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
CO2018001268A2 (es) Derivados de heteroarilo como inhibidores de parp
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
CO6410258A2 (es) Compuestos de piridazinona
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
CO2017009994A2 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CO2018010787A2 (es) Compuesto de griseofulvina
CR20160600A (es) Quinolizione derivados como inhibidores pi3k
AR100439A1 (es) Derivados de carboxamida
AR127705A1 (es) Heterociclos inhibidores de nlrp3
BR112018003489A2 (pt) n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
CO2018007788A2 (es) Compuesto novedoso de ácido bisfosfónico

Legal Events

Date Code Title Description
FB Suspension of granting procedure